Related Articles by Review for PMID: 22250165

Year	Number of Results
2008	1
2011	4
2012	14
2024	0

1

Rivaroxaban reduced stroke and systemic embolism compared with warfarin in nonvalvular AF.

Klein L. Klein L. Ann Intern Med. 2012 Jan 17;156(2):JC1-2, JC1-3. doi: 10.7326/0003-4819-156-2-201201170-02003. Ann Intern Med. 2012. PMID: 22250165 No abstract available.

2

Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.

Paikin JS, Manolakos JJ, Eikelboom JW. Paikin JS, et al. Expert Rev Cardiovasc Ther. 2012 Aug;10(8):965-72. doi: 10.1586/erc.12.91. Expert Rev Cardiovasc Ther. 2012. PMID: 23030284 Review.

3

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

Deedwania PC, Huang GW. Deedwania PC, et al. Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 21740079 Review.

4

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY. Potpara TS, et al. Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Adv Ther. 2012. PMID: 22684583 Review.

5

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M. Uchiyama S, et al. J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. J Stroke Cerebrovasc Dis. 2012. PMID: 22440950 Review.

6

Role of new drugs for management of atrial fibrillation.

Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM. Hollands JM, et al. Ann Pharmacother. 2012 Dec;46(12):1656-70. doi: 10.1345/aph.1R155. Epub 2012 Dec 18. Ann Pharmacother. 2012. PMID: 23249869 Review.

7

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.

Agarwal S, Hachamovitch R, Menon V. Agarwal S, et al. Arch Intern Med. 2012 Apr 23;172(8):623-31; discussion 631-3. doi: 10.1001/archinternmed.2012.121. Epub 2012 Mar 26. Arch Intern Med. 2012. PMID: 22450212 Review.

8

Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.

Yates SW. Yates SW. Hosp Pract (1995). 2011 Oct;39(4):7-16. doi: 10.3810/hp.2011.10.918. Hosp Pract (1995). 2011. PMID: 22056819 Review.

9

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J. Mantha S, et al. Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Thromb Haemost. 2012. PMID: 22740145 Review.

10

A review of oral anticoagulants in patients with atrial fibrillation.

Greenspon AJ. Greenspon AJ. Postgrad Med. 2012 Nov;124(6):7-16. doi: 10.3810/pgm.2012.11.2608. Postgrad Med. 2012. PMID: 23322134 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

19 results

Results by year